echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The U.S. FDA approves the expansion of the use of Ultomiris

    The U.S. FDA approves the expansion of the use of Ultomiris

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alexion Pharma recently announced that the U.


    Ultomiris is a long-acting C5 complement inhibitor that can inhibit the C5 protein in the complement cascade of the human immune system, and can provide immediate, complete and sustained complement inhibition


    Since it was first approved in 2018, Ultomiris has quickly become the standard treatment for adult patients with PNH in the United States


    Ultomiris is designed to inhibit the C5 protein in the terminal part of the complement cascade, while retaining the functions of other parts of the immune system to resist common pathogens and infections


    This approval is based on the results of a phase 3 clinical study


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.